Innolake Biopharm

Executive Summary

Innolake Biopharm is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focused on developing differentiated monoclonal antibody and fusion protein therapies for oncology and autoimmune diseases. Founded in 2012, the company employs a target-centric approach to create novel biologics with unique mechanisms of action. Innolake has advanced multiple candidates into clinical development, including phase 3 trials in China, and is expanding its global footprint. The company's pipeline targets key pathways in solid tumors and inflammatory disorders, aiming to address unmet medical needs with next-generation therapeutics. With a strong emphasis on innovation and a robust discovery platform, Innolake is positioned to become a significant player in the Chinese biopharma landscape and potentially partner with global pharmaceutical companies for late-stage development and commercialization.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 data readout for lead asset in solid tumors (e.g., PD-1/PD-L1 bispecific)70% success
• Q2 2027NDA submission for autoimmune candidate (e.g., IL-17A inhibitor) in China60% success
• Q3 2026Out-licensing or co-development deal with a global pharma for a preclinical candidate50% success